Medical Citations

Gleam – Nutrition & Peptide Tracking Journal

Effective Date: May 28, 2026
Last Updated: May 28, 2026

Gleam is designed for private nutrition tracking, wellness journaling, peptide-related recordkeeping, and general educational support only. The app does not diagnose, treat, prevent, cure, monitor, or manage any disease, medical condition, nutritional disorder, hormonal condition, metabolic condition, psychiatric condition, adverse event, medication regimen, peptide protocol, or supplement protocol.

Gleam does not provide medical advice, dietary treatment advice, peptide advice, medication advice, supplement advice, diagnosis, treatment recommendations, dosage recommendations, injection instructions, sourcing guidance, prescribing guidance, clinical decision support, emergency monitoring, or professional healthcare evaluation. Gleam does not sell, prescribe, recommend, source, advertise, link to, facilitate, verify, or provide peptides, medications, compounded drugs, supplements, controlled substances, research chemicals, pharmacies, clinics, vendors, prescribers, or medical products.

Gleam’s nutrition estimates, food-image analysis, wellness summaries, Gleam Score, Evidence Level labels, Safety Level labels, peptide-related summaries, and AI-generated outputs are private, app-generated estimates based on information you choose to enter or upload. These outputs are intended for personal organization and general education only. They are not medical determinations, clinical findings, regulatory approvals, safety certifications, effectiveness claims, or substitutes for a licensed physician, pharmacist, registered dietitian, or other qualified healthcare professional.

The live Gleam Terms of Use describe Gleam as a general wellness, nutrition, and personal logging tool, not a medical device, pharmacy, peptide supplier, clinical decision-support tool, diagnostic tool, dosage calculator, or substitute for professional medical advice. The live Privacy Policy similarly states that Gleam is a private nutrition, wellness, journaling, reminder, and self-tracking tool, and that it does not sell, prescribe, recommend, source, facilitate, verify, approve, or provide peptides, medications, compounded drugs, research chemicals, supplements, controlled substances, or medical products.

Sources & Citations

Regulatory Review and Evidence Levels

Gleam’s Evidence Level labels are educational summaries of the maturity and quality of publicly available information. They are not medical determinations, clinical recommendations, regulatory approvals, safety certifications, or effectiveness claims.

FDA explains that drug development generally involves discovery, preclinical research, clinical research, FDA review, and post-market safety monitoring. This supports Gleam’s distinction between lower-maturity public research, human clinical evidence, and regulatory-grade review.

Source: U.S. Food & Drug Administration — “Development & Approval Process | Drugs”
Link: https://www.fda.gov/drugs/development-approval-process-drugs
Citation: U.S. Food & Drug Administration. “Development & Approval Process | Drugs.” FDA. 2022.

FDA’s current public guidance explains that not everything described as “FDA approved” is actually FDA-approved, and that FDA does not approve dietary supplements for safety and effectiveness. This supports Gleam’s disclaimers that evidence or safety labels should not be interpreted as approval, clearance, suitability, legality, or permission to use a product.

Source: U.S. Food & Drug Administration — “Is It Really ‘FDA Approved’?”
Link: https://www.fda.gov/consumers/consumer-updates/it-really-fda-approved
Citation: U.S. Food & Drug Administration. “Is It Really ‘FDA Approved’?” FDA Consumer Updates. 2026.

The Gleam Evidence and Safety Disclaimer states that Evidence Level may consider published clinical research, human trial availability, clinical trial phase, peer-reviewed publication history, study size, consistency of findings, use-case relevance, and regulatory-grade review. It also states that Evidence Level labels are educational summaries and not medical determinations, regulatory approvals, safety certifications, or substitutes for licensed professional advice.

Safety Levels, Adverse Events, and Pharmacovigilance

Gleam’s Safety Level labels are educational summaries of publicly available safety and regulatory information. They are not guarantees that any peptide, medication, supplement, compound, source, formulation, dose, route, or intended use is safe, legal, effective, appropriate, or personally suitable.

WHO defines pharmacovigilance as the science and activities related to detecting, assessing, understanding, and preventing adverse effects or other medicine-related problems. This supports Gleam’s disclaimer that the app is not an adverse-event monitoring system and does not perform pharmacovigilance.

Source: World Health Organization — “Pharmacovigilance”
Link: https://www.who.int/teams/regulation-prequalification/regulation-and-safety/pharmacovigilance
Citation: World Health Organization. “Pharmacovigilance.” WHO Regulation and Prequalification.

FDA describes post-market drug safety monitoring as a stage in the drug development and approval process. This supports the distinction between regulated post-market safety systems and Gleam’s private user-directed journaling.

Source: U.S. Food & Drug Administration — “The Drug Development Process”
Link: https://www.fda.gov/patients/learn-about-drug-and-device-approvals/drug-development-process
Citation: U.S. Food & Drug Administration. “The Drug Development Process.” FDA. 2018.

The Gleam Evidence and Safety Disclaimer states that Safety Level may consider whether a specific peptide-based drug product has been reviewed or approved by FDA, EMA, or another recognized medical regulator; whether human safety data exists; whether post-market monitoring exists; whether adverse-event information has been published; and whether reputable clinical or governmental bodies have evaluated the product or compound. It also states that a high safety label does not mean risk-free, safe for every person, safe at every dose, safe from every source, or safe through every route.

Peptides, Compounded Drugs, and Regulatory Limitations

Gleam may allow users to manually log peptide-related information for private organization. That logging functionality does not mean Gleam recommends peptide use, endorses peptide use, verifies peptide safety, evaluates legality, or determines whether any substance is appropriate for a user.

FDA states that compounded drugs are not FDA-approved and that FDA does not verify the safety, effectiveness, or quality of compounded drugs before they are marketed. This supports Gleam’s disclaimer that user-entered peptide or compound information should not be interpreted as verified, approved, safe, legal, pure, sterile, effective, or suitable.

Source: U.S. Food & Drug Administration — “Compounding and the FDA: Questions and Answers”
Link: https://www.fda.gov/drugs/human-drug-compounding/compounding-and-fda-questions-and-answers
Citation: U.S. Food & Drug Administration. “Compounding and the FDA: Questions and Answers.” FDA. 2025.

FDA has identified potential significant safety risks for certain bulk drug substances proposed for use in compounding, including some peptide-related substances. This supports Gleam’s conservative posture that it does not determine the safety, legality, regulatory status, or medical appropriateness of any peptide or compound.

Source: U.S. Food & Drug Administration — “Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks”
Link: https://www.fda.gov/drugs/human-drug-compounding/certain-bulk-drug-substances-use-compounding-may-present-significant-safety-risks
Citation: U.S. Food & Drug Administration. “Certain Bulk Drug Substances for Use in Compounding May Present Significant Safety Risks.” FDA. 2026.

FDA has also warned about unapproved GLP-1 drugs used for weight loss, including products sold directly to consumers and falsely labeled for research purposes or not for human consumption. This supports Gleam’s “no sourcing, no sales, no vendor verification, no dosing, no procurement” posture for peptide-related or peptide-adjacent products.

Source: U.S. Food & Drug Administration — “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss”
Link: https://www.fda.gov/drugs/postmarket-drug-safety-information-patients-and-providers/fdas-concerns-unapproved-glp-1-drugs-used-weight-loss
Citation: U.S. Food & Drug Administration. “FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss.” FDA. 2026.

The Gleam Terms of Use state that Gleam does not recommend peptides, endorse peptide use, provide peptide protocols, provide peptide dosing guidance, calculate peptide doses, recommend injection frequency, provide sourcing instructions, or connect users with peptide sellers, clinics, pharmacies, vendors, suppliers, prescribers, compounders, or marketplaces.

Off-Label Use, Unapproved Uses, and Product-Specific Approval

Gleam’s peptide-related and evidence-related information should not be interpreted as approval for off-label use, non-approved use, compounded use, research-chemical use, or any user-specific intended use.

FDA explains that off-label use means an approved drug is used for an unapproved disease or medical condition, and that such decisions are matters to discuss with a healthcare provider. This supports Gleam’s position that users must not treat app content as off-label guidance or individualized treatment advice.

Source: U.S. Food & Drug Administration — “Understanding Unapproved Use of Approved Drugs ‘Off Label’”
Link: https://www.fda.gov/patients/learn-about-expanded-access-and-other-treatment-options/understanding-unapproved-use-approved-drugs-label
Citation: U.S. Food & Drug Administration. “Understanding Unapproved Use of Approved Drugs ‘Off Label.’” FDA. 2018.

FDA’s public guidance states that after FDA approves a drug for a disease or condition, healthcare professionals may prescribe or administer it for an unapproved use based on medical judgment, while recognizing FDA has not approved the drug for that use. This supports Gleam’s disclaimer that any regulatory approval is product-, indication-, formulation-, route-, population-, and labeling-specific.

Source: U.S. Food & Drug Administration — “Understanding FDA Terms for Possible New Therapies to Prevent and Treat Diseases”
Link: https://www.fda.gov/consumers/consumer-updates/understanding-fda-terms-possible-new-therapies-prevent-and-treat-diseases
Citation: U.S. Food & Drug Administration. “Understanding FDA Terms for Possible New Therapies to Prevent and Treat Diseases.” FDA Consumer Updates. 2025.

The Gleam Evidence and Safety Disclaimer states that FDA approval of a specific product does not mean all versions, sources, compounded forms, off-label uses, research-chemical versions, or non-approved uses of that peptide are approved or safe.

No Sales, Sourcing, Prescribing, or Vendor Verification

Gleam does not sell peptides, prescribe peptides, recommend suppliers, verify sellers, facilitate transactions, provide compounding instructions, or guarantee the identity, legality, purity, sterility, concentration, stability, quality, safety, or effectiveness of any peptide or peptide-related product.

FDA warns that unsafe online pharmacies may sell unapproved, counterfeit, or otherwise unsafe medicines outside the safeguards followed by licensed pharmacies. This supports Gleam’s strict position that it does not facilitate sourcing, purchasing, pharmacy referrals, seller verification, or procurement.

Source: U.S. Food & Drug Administration — “How to Buy Medicines Safely From an Online Pharmacy”
Link: https://www.fda.gov/consumers/consumer-updates/how-buy-medicines-safely-online-pharmacy
Citation: U.S. Food & Drug Administration. “How to Buy Medicines Safely From an Online Pharmacy.” FDA Consumer Updates. 2025.

FDA states that counterfeit medicines may contain the wrong ingredients, too much, too little, or no active ingredient, or other harmful ingredients. This supports Gleam’s disclaimer that it does not verify product identity, quality, purity, potency, concentration, source, sterility, or safety.

Source: U.S. Food & Drug Administration — “Counterfeit Medicine”
Link: https://www.fda.gov/drugs/buying-using-medicine-safely/counterfeit-medicine
Citation: U.S. Food & Drug Administration. “Counterfeit Medicine.” FDA. 2025.

The Gleam Evidence and Safety Disclaimer states that Gleam does not sell peptides, prescribe peptides, provide dosing instructions, recommend suppliers, verify third-party sellers, facilitate transactions, provide compounding instructions, or guarantee the identity, legality, purity, sterility, concentration, stability, quality, safety, or effectiveness of any peptide-related product.

Dietary Supplements and Supplement-Related Information

Gleam may allow users to log supplement-related information. Logging a supplement does not mean Gleam recommends, verifies, approves, validates, or determines the safety, legality, effectiveness, or appropriateness of that supplement.

NIH’s Office of Dietary Supplements explains that FDA does not determine whether dietary supplements are effective before they are marketed. This supports Gleam’s disclaimer that supplement-related entries and summaries are not medical advice, safety certifications, effectiveness claims, or regulatory approvals.

Source: NIH Office of Dietary Supplements — “Dietary Supplements: What You Need to Know”
Link: https://ods.od.nih.gov/factsheets/WYNTK-Consumer/
Citation: NIH Office of Dietary Supplements. “Dietary Supplements: What You Need to Know.” National Institutes of Health. 2023.

FDA states that, under DSHEA, FDA is not authorized to approve dietary supplements for safety and effectiveness before they are marketed, and that many firms can introduce supplements to market without notifying FDA. This supports Gleam’s warning that supplement entries should not be treated as proof of safety, legality, effectiveness, or suitability.

Source: U.S. Food & Drug Administration — “Information for Consumers on Using Dietary Supplements”
Link: https://www.fda.gov/food/dietary-supplements/information-consumers-using-dietary-supplements
Citation: U.S. Food & Drug Administration. “Information for Consumers on Using Dietary Supplements.” FDA. 2022.

FDA also states that it generally does not approve dietary supplement claims or labeling before use, and that firms are responsible for ensuring their dietary supplements are not adulterated, misbranded, or otherwise unlawful. This supports Gleam’s position that it does not verify supplement claims, labeling, safety, purity, strength, composition, or legal compliance.

Source: U.S. Food & Drug Administration — “Questions and Answers on Dietary Supplements”
Link: https://www.fda.gov/food/information-consumers-using-dietary-supplements/questions-and-answers-dietary-supplements
Citation: U.S. Food & Drug Administration. “Questions and Answers on Dietary Supplements.” FDA. 2024.

Nutrition Tracking and General Dietary Education

Gleam may provide nutrition logs, calorie estimates, macro estimates, hydration tracking, food-image analysis, and general educational summaries. These outputs are approximate and should not be used as medical nutrition therapy, diagnosis, treatment, or disease-management advice.

The Dietary Guidelines for Americans provide federal advice on what to eat and drink to meet nutrient needs, promote health, and help prevent disease. This supports Gleam’s use of general nutrition education while reinforcing that individualized medical nutrition decisions should be made with qualified professionals.

Source: U.S. Dietary Guidelines — “Dietary Guidelines for Americans”
Link: https://www.dietaryguidelines.gov/
Citation: U.S. Department of Agriculture and U.S. Department of Health and Human Services. “Dietary Guidelines for Americans.”

The CDC explains that healthy eating patterns emphasize vegetables, fruits, protein, dairy without added sugars, healthy fats, and whole grains, and are generally low in added sugars, sodium, saturated fats, trans fats, and cholesterol. This supports broad nutrition education, not individualized treatment claims.

Source: https://pmc.ncbi.nlm.nih.gov/articles/PMC7478086/

Influenced nutritional algorithm.

Source: Centers for Disease Control and Prevention — “Tips for Healthy Eating for a Healthy Weight”
Link: https://www.cdc.gov/healthy-weight-growth/healthy-eating/index.html
Citation: Centers for Disease Control and Prevention. “Tips for Healthy Eating for a Healthy Weight.” CDC. 2026.

The CDC states that nutrition guidelines and recommendations can inform public health approaches to improving nutrition. This supports Gleam’s general educational nutrition content while preserving the distinction between public health education and personalized clinical advice.

Source: Centers for Disease Control and Prevention — “Nutrition Guidelines and Recommendations”
Link: https://www.cdc.gov/nutrition/php/guidelines-recommendations/index.html
Citation: Centers for Disease Control and Prevention. “Nutrition Guidelines and Recommendations.” CDC. 2026.

The Gleam Support page states that Gleam provides nutrition insights, tracking tools, and AI-generated suggestions for informational and educational purposes only; that Gleam is not a medical device; that it does not provide medical advice, diagnosis, or treatment; and that users should consult a qualified healthcare professional before making dietary or health decisions.

Calorie Estimates, Weight, and Body Composition Limitations

Gleam may estimate calories, macros, and nutrition information based on user entries or food images. These estimates may be incomplete or inaccurate and should not be treated as clinical measurements.

NIH’s NIDDK describes its Body Weight Planner as a tool that allows users to make personalized calorie and physical activity plans to reach a goal weight and maintain it. This source supports the general idea that calorie and activity estimates can be used for planning, while Gleam should still avoid presenting its own estimates as medical advice or guaranteed outcomes.

Source: NIH / NIDDK — “About the Body Weight Planner”
Link: https://www.niddk.nih.gov/health-information/weight-management/body-weight-planner
Citation: National Institute of Diabetes and Digestive and Kidney Diseases. “About the Body Weight Planner.” NIH.

NIDDK explains that the Body Weight Planner is about calculating how the body may respond to changes in calories from diet and physical activity. This supports the broader methodology of using calorie-related inputs for estimates while reinforcing that estimates are modeled and should be interpreted cautiously.

Source: NIH / NIDDK — “NIH Body Weight Planner”
Link: https://www.niddk.nih.gov/health-information/professionals/diabetes-discoveries-practice/nih-body-weight-planner
Citation: National Institute of Diabetes and Digestive and Kidney Diseases. “NIH Body Weight Planner.” NIH. 2018.

The Gleam Terms of Use state that nutrition estimates, including calories, macros, BMI, and nutrients, are approximations and may be inaccurate, and that AI-generated outputs may be incomplete, incorrect, or unsuitable for a user’s specific needs.